Top melanoma Articles in Dermatology

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/2009

Lin H et al. – Our data indicate that SNF5 may be an important marker for human melanoma progression and prognosis as well as a potential therapeutic target. Methods Using tissue microarry and ... melanomas, and 48 metastatic melanomas evaluated Studied chemosensitivity of melanoma cells with reduced SNF5 expression by siRNA using cell survival and apoptosis assays Results SNF5 expression reduced in metastatic melanoma compared with dysplastic nevi , in ... advanced primary melanoma (Clark's level V) compared with low risk Clark's level II melanoma , and in melanoma at sun-exposed sites compared with sun-protected sites Strong correlation between negative SNF5 expression and worse 5-year survival in melanoma patients Multivariate Cox ... analysis revealed negative SNF5 expression is independent prognostic factor to predict patient outcome in primary melanomas Knockdown of SNF5 in melanoma cell lines resulted in significant chemoresistance [more...]

Slow-growing melanoma: a dermoscopy follow-up study
British Journal of Dermatology, 10/05/2009

Argenziano G et al. – The study provides evidence for the existence of a subgroup of slow–growing melanomas, which may explain the increase in the incidence of thin melanoma, despite stable rates of thick melanoma and melanoma&ndash ... mortality. [more...]

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Journal of Investigative Dermatology, 11/03/2009

Gutwein P et al. – The authors data demonstrate that ADAM10 and L1–CAM have important roles during melanoma progression and both molecules represent attractive targets for therapeutical intervention of melanomas. [more...]

KIT as a Therapeutic Target in Melanoma
Journal of Investigative Dermatology, 10/23/2009

Bastian BC et al. – Emerging evidence suggests that melanomas with KIT activation may also respond to KIT inhibitors that are already in clinical use. If confirmed in ongoing clinical trials, this experience would underscore the importance of ... among melanomas, representing a first decisive step toward the individualized and mechanism–based treatment of melanoma. [more...]

Distinct MHC gene expression patterns during progression of melanoma
Genes, Chromosomes and Cancer, 11/02/2009

Degenhardt Y et al. – These results infer a dynamic role of MHC function in melanoma progression. The authors propose potential mechanisms for the overexpression of MHC molecules in earlier stages of melanoma as well as for its downregulation in metastatic melanomas. [more...]

Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma
Pigment Cell & Melanoma Research, 10/19/2009

Takata M et al. – Amplifications of the cyclin D1 gene are detected in normal–looking 'field melanocytes', which represent a latent progression phase of acral melanoma that precedes ... atypical melanocyte proliferation in the epidermis. [more...]

Malignant melanoma: how error amplification by screening creates spurious disease
British Journal of Dermatology, 10/12/2009

Shuster S – The artefact of error amplification by screening detracts from a possible role for ultraviolet radiation in the increase in melanoma incidence and provides an explanation of their erroneous ... addition to melanoma, it could be a major source of misdiagnosis of other cancers associated with patient screening programmes. [more...]

Positron emission tomography in early detection of relapse in high-risk melanoma patients: a retrospective review
Community Oncology, 10/09/2009

Kottschade LA et al. – To determine the usefulness of FDG–PET in the surveillance of melanoma patients at high risk of relapse, the authors reviewed the medical records of ... for high–risk melanoma patients may be a useful tool for early identification of asymptomatic relapse amenable to complete surgical resection. [more...]

Childhood melanoma
Clinics in Dermatology, 11/05/2009

Jen M et al. – Pediatric melanoma is rare but increasing in incidence. Because early diagnosis and treatment improves prognosis, clinicians need to include it as a possible diagnosis when evaluating a pigmented lesion in a pediatric patient. Some risk factors for melanoma include ... xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression. [more...]

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/2009

Eisen T et al. – The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported. This study showed ... malignant melanoma but no benefit in tumor response, time to progression, or overall survival in these patients. Methods Compared treatment with lenalidomide (25 mg/d on Days 1-21 of a 28-day cycle) to placebo in 306 patients with metastatic malignant melanoma [more...]